Theramex, a global specialty pharmaceutical company focused on women’s health, is set to acquire European rights for Duphaston® and Femoston® from Viatris Inc., while Viatris retains rights for Australia and Japan. The deal awaits standard regulatory and antitrust approvals. Theramex’s CEO, Rob Stewart, sees this move as an opportunity to enhance their Menopause portfolio and provide better access to quality treatments in women’s health, including hormone replacement therapy with Duphaston® and Femoston®.
Theramex, a leading global specialty pharmaceutical company dedicated to women’s health, is pleased to announce that it has agreed to acquire the European rights to Duphaston® and Femoston® from Viatris Inc. Viatris retains the rights for Australia and Japan. The transaction is subject to customary regulatory and anti-trust approvals.
“As we continue to strengthen our commitment to women’s health and improve our patient’s access to high-quality treatments, we are excited to acquire new products to expand our Menopause portfolio.” – Rob Stewart, CEO of Theramex.
Duphaston® (dydrogesterone) and Femoston® (estradiol/dydrogesterone) may be prescribed in indications related to hormone replacement therapy (HRT).
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.